|
Name |
6-Hydroxylpaspalinine
|
| Molecular Formula | C27H31NO4 | |
| IUPAC Name* |
(1R,2R,4S,5S,16S,19R,23R)-2-hydroxy-4,5,24,24-tetramethyl-25,26-dioxa-7-azaheptacyclo[21.2.1.01,20.04,19.05,16.06,14.08,13]hexacosa-6(14),8,10,12,20-pentaen-22-one
|
|
| SMILES |
C[C@]12C[C@H]([C@]34C(=CC(=O)[C@H](O3)C(O4)(C)C)[C@@H]1CC[C@@H]5[C@@]2(C6=C(C5)C7=CC=CC=C7N6)C)O
|
|
| InChI |
InChI=1S/C27H31NO4/c1-24(2)23-20(29)12-18-17-10-9-14-11-16-15-7-5-6-8-19(15)28-22(16)26(14,4)25(17,3)13-21(30)27(18,31-23)32-24/h5-8,12,14,17,21,23,28,30H,9-11,13H2,1-4H3/t14-,17-,21+,23-,25-,26+,27+/m0/s1
|
|
| InChIKey |
SMUWWVMLCRYVKW-GOJHYGRYSA-N
|
|
| Synonyms |
6-hydroxylpaspalinine
|
|
| CAS | NA | |
| PubChem CID | 139590473 | |
| ChEMBL ID | NA |
Chemical Classification: |
|
|
|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
|---|---|---|---|---|---|---|---|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
| Molecular Weight: | 433.5 | ALogp: | 3.6 |
| HBD: | 2 | HBA: | 4 |
| Rotatable Bonds: | 0 | Lipinski's rule of five: | Accepted |
| Polar Surface Area: | 71.6 | Aromatic Rings: | 7 |
| Heavy Atoms: | 32 | QED Weighted: | 0.628 |
| Caco-2 Permeability: | -5.233 | MDCK Permeability: | 0.00002280 |
| Pgp-inhibitor: | 0.998 | Pgp-substrate: | 0.502 |
| Human Intestinal Absorption (HIA): | 0.003 | 20% Bioavailability (F20%): | 0.022 |
| 30% Bioavailability (F30%): | 0.556 |
| Blood-Brain-Barrier Penetration (BBB): | 0.861 | Plasma Protein Binding (PPB): | 94.10% |
| Volume Distribution (VD): | 2.069 | Fu: | 2.80% |
| CYP1A2-inhibitor: | 0.07 | CYP1A2-substrate: | 0.967 |
| CYP2C19-inhibitor: | 0.195 | CYP2C19-substrate: | 0.885 |
| CYP2C9-inhibitor: | 0.299 | CYP2C9-substrate: | 0.042 |
| CYP2D6-inhibitor: | 0.035 | CYP2D6-substrate: | 0.244 |
| CYP3A4-inhibitor: | 0.836 | CYP3A4-substrate: | 0.862 |
| Clearance (CL): | 5.639 | Half-life (T1/2): | 0.116 |
| hERG Blockers: | 0.042 | Human Hepatotoxicity (H-HT): | 0.562 |
| Drug-inuced Liver Injury (DILI): | 0.23 | AMES Toxicity: | 0.843 |
| Rat Oral Acute Toxicity: | 0.989 | Maximum Recommended Daily Dose: | 0.96 |
| Skin Sensitization: | 0.539 | Carcinogencity: | 0.953 |
| Eye Corrosion: | 0.003 | Eye Irritation: | 0.012 |
| Respiratory Toxicity: | 0.985 |
| Similar NPs | Similar Drugs | ||||||
|---|---|---|---|---|---|---|---|
| NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
| ENC005990 | ![]() |
0.613 | D0H4JM | ![]() |
0.289 | ||
| ENC005988 | ![]() |
0.596 | D0U7GP | ![]() |
0.289 | ||
| ENC003928 | ![]() |
0.569 | D01JGV | ![]() |
0.289 | ||
| ENC002279 | ![]() |
0.566 | D06CWH | ![]() |
0.277 | ||
| ENC000836 | ![]() |
0.517 | D02QJH | ![]() |
0.275 | ||
| ENC003172 | ![]() |
0.513 | D02JNM | ![]() |
0.274 | ||
| ENC005989 | ![]() |
0.513 | D05MQK | ![]() |
0.270 | ||
| ENC002951 | ![]() |
0.509 | D06IIB | ![]() |
0.270 | ||
| ENC005405 | ![]() |
0.504 | D0P0HT | ![]() |
0.266 | ||
| ENC005406 | ![]() |
0.500 | D03ZZK | ![]() |
0.260 | ||